CONTEXT: The combination of ultrasound and near-infrared (NIR) optical tomography employs the functional parameters of tumor hemoglobin distribution and oxygen saturation as an adjunct to ultrasound and x-ray mammography for accurate diagnosis of breast cancer. Quing Zhu, Ph.D., an associate professor of bioengineering, and her collaborators at the University of Connecticut Health Center, led by Dr. Scott Kurtzman, and Hartford Hospital, led by Dr. Edward Cronin, performed a preliminary clinical trial of the hybrid technique in more than 100 patients scheduled for breast biopsies.
RESULTS: Coregistered ultrasound images and NIR optical data were acquired simultaneously from each patient, using a handheld probe housing a commercial ultrasound transducer and optical sources and detectors. The novel optical imaging technique invented by Zhu took advantage of ultrasound localization and reconstructed lesions with a finer grid than that of background tissue. As a result, the quantification of lesion light absorption-and, therefore, total hemoglobin concentration-was significantly improved. Initial results revealed about twice the hemoglobin concentration in invasive cancers as in benign lesions.
IMPLICATIONS: Initial findings suggest that hybrid ultrasound/optical imaging may provide a low-cost, noninvasive, highly specific way to diagnose breast cancers, especially those that are small and aggressive, Zhu said. The next step involves using the technique to monitor the response of breast cancer to chemotherapy.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.